Shares of Allogene Therapeutics Inc (ALLO) are trading 11% higher at a price of $13.15 at the time of this writing.

Allogene Therapeutics Inc has been trading between a 52-week high of $27.86 and a 52-week low of $6.43. The stock has a market cap of $1.89 Billion.

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

If You Don’t Bullish On Allogene Therapeutics Inc. (NASDAQ: ALLO) Now, You’ll Regret Your Decision Later
Stocks Register 07-12-22

Allogene Therapeutics Inc. (ALLO): Why Is The Stock Strong?
Marketing Sentinel 06-29-22

Allogene Therapeutics Inc. (NASDAQ: ALLO): What’s Next In 2022?
Stocks Register 06-24-22

Allogene Therapeutics: Multibagger Potential, Terribly Risky (NASDAQ:ALLO)
Seeking Alpha 06-24-22

Allogene Therapeutics Inc.’s Stock Gains 16.35%, But It May Still Be Worth Investing In.
Stocks Register 06-21-22